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Abstract 
Protontherapy is hadrontherapy’s fastest-growing modality and a pillar in the battle against cancer.  
Hadrontherapy’s superiority lies in its inverted depth-dose profile, hence tumour-confined 
irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. 
Higher LET (Linear Energy Transfer) 12C-ions can overcome cancer radioresistance: DNA lesion 
complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological 
Effectiveness (RBE). However, economic and radiobiological issues hamper 12C-ion clinical 
amenability. Thus, enhancing proton RBE is desirable. To this end, we exploited the p + 11Bà3a 
reaction to generate high-LET alpha particles with a clinical proton beam. To maximize the reaction 
rate, we used sodium borocaptate (BSH) with natural boron content. Boron-Neutron Capture 
Therapy (BNCT) uses 10B-enriched BSH for neutron irradiation-triggered alpha-particles. We 
recorded significantly increased cellular lethality and chromosome aberration complexity. A 
strategy combining protontherapy’s ballistic precision with the higher RBE promised by BNCT and 
12C-ion therapy is thus demonstrated.	
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The urgent need for radical radiotherapy research to achieve improved tumour control in the context 
of reducing the risk of normal tissue toxicity and late-occurring sequelae, has driven the fast-
growing development of cancer treatment by accelerated beams of charged particles 
(hadrontherapy) in recent decades (1). This appears to be particularly true for protontherapy, which 
has emerged as the most-rapidly expanding hadrontherapy approach, totalling over 100,000 patients 
treated thus far worldwide (2). The use of energetic protons for cancer radiotherapy was first 
proposed by Wilson in 1946 (3). The primary motivation for investigation into this area was based 
on the physical properties of charged particles, which can deposit energy far more selectively than 
photons: through the inverted depth-dose profile described by the Bragg curve (4), healthy tissues 
within the entry channel of the beam are spared of dose, while most of the dose is steeply confined 
at the end of the particle range (the so-called “Bragg peak”).  This in principle enables the delivery 
of very high-dose gradients close to organs at risk, confining the high-dose area to the tumour 
volume. Despite the dearth of randomized trials showing an effective advantage of protons over 
photon-based radiotherapy (5,6) and the ongoing debate over its cost-effectiveness (7), the current 
phase I/II clinical results support the rationale of the approach, especially for deep-seated tumours 
localized in proximity of critical organs, and unresectable or recurrent tumours (8,9).	 Cancer 
treatment by protons also remains the most attractive solution in the case of paediatric patients due 
to the significant reduction in the integral dose delivered to the patient (8), even compared to newer 
photon techniques such as intensity modulated radiation therapy (10). However, protons have been 
traditionally regarded as only slightly more biologically effective than photons (11). In fact, the 
standard practice in protontherapy is to adopt an RBE (Relative Biological Effectiveness) value of 
1.1 compared to photons in any clinical condition (12), although such an assumption overlooks the 
increased RBE of low-energy protons (13-15) disregarding recently unveiled peculiarities of proton 
radiobiology (8,16,17).  
The combination of ballistic precision with an increased ability to kill cells is the radiobiological 
rationale currently supporting the clinical exploitation of heavier particles such as fully stripped 
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12C-ions (19), which present some advantages over protons (6, 19). Not only do they ensure a better 
physical dose distribution, due to less lateral scattering (20), but they are also more biologically 
effective both in vitro and in vivo as a result of their higher Linear Energy Transfer (LET) 
(11,21,22). In fact, densely ionizing radiation tracks cause more spatio-temporally contiguous and 
complex lesions at the DNA level, comprising DNA double-strand breaks and damaged bases, 
which are highly clustered in nature (23-25). This impairs cellular ability for correct repair (26) and 
decreases the dependence of radiosensitization upon the presence of oxygen, desirable features for 
eradication of resilient, hypoxic tumors (5, 27). Further potential radiobiological advantages include 
greater RBE for killing putatively radioresistant cancer stem cells (28) and counteracting cancer 
invasiveness (29, 30), albeit the latter remains controversial (31). Finally, low doses of high-LET 
radiation appear to elicit stronger immunological responses compared to low-LET radiation (17).  
On the other hand, nuclear fragmentation reactions incurred by the primary beam partially spoil the 
12C superior dose distribution, depositing unwanted dose behind the target volume, as opposed to 
the sharp dose fall-off that characterizes protons (32). Moreover, there exists a substantial lack of 
understanding of the impact on normal cells of the exposure to high-LET radiation. While it is true 
that preliminary reports on the follow-up of patients treated with 12C ions do not show an increased 
incidence of secondary cancers (33), uncertainties surround the effectiveness with which high-LET 
radiations such as 12C ions cause non-cancer effects that can have clinical repercussions. As a 
matter of fact, mounting evidence seems to indicate that 12C ions are particularly effective at 
causing pro-inflammatory responses leading to cardiovascular complications and premature cellular 
senescence even at low doses, i.e. those absorbed by the traversed healthy tissues (34-36). Taken 
together, these findings warrant further radiobiological investigation on the possible after effects 
arising from 12C hadrontherapy. Finally, a major hindrance to a greater diffusion of 12C 
hadrontherapy, which remains limited to a few centres, is caused by the complexity of their 
acceleration, transport and handling, delivery to the patient and dosimetry. These are more 
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complicated compared to proton beams, leading to an increase of the initial investment and overall 
running costs of 12C-ion therapy centers (37).  
In order to overcome such limitations, different strategies are being explored with the aim to 
achieve alternative solutions for a localized increase of proton RBE. One of the recently proposed 
approaches foresees the use of gold nanoparticles as protontherapy radiosensitizers (38). The ability 
of particle radiation to stimulate favourable immunological responses represents another attractive 
solution as it has become increasingly evident that proton and photon irradiation differentially 
modulate systemic biological responses (8, 17). 
In this work, we experimentally demonstrate for the first time that the p + 11B à3a nuclear fusion 
reaction, which is known to generate short-range high-LET alpha particles (39, 40), can be 
exploited to enhance proton biological effectiveness exclusively in the tumour region, and thus is of 
potential clinical worth. Cells were irradiated with a clinical proton beam in the presence of sodium 
borocaptate (NA2B12H11SH or “BSH”), which is a common agent used in BNCT) in its 10B-
enriched form to selectively deliver boron in cancer cells (41). BNCT requires thermal neutrons to 
trigger the reaction where a single alpha particle with maximum energy of around 2.7 MeV and 
range in tissue of less than 10 µm is produced (42). In order to maximize the p + 11B	à3a	fusion 
rate, we used the compound with natural occurring boron isotopic abundance (i.e. 80% 11B and 20% 
10B). We observed a significant increase in proton-induced cytogenetic effects, both in terms of cell 
death, assessed as loss of proliferative potential by the clonogenic cell survival, and of induction of 
DNA damage. The latter was studied by chromosome aberrations revealed by Fluorescence-in Situ 
Hybridization (FISH) painting. Specifically, the markedly higher frequency of complex-type 
chromosome exchanges (a typical cytogenetic signature of high-LET ionizing radiation, see ref. 43 
for example), which was found among boron-treated cells compared to proton-irradiated cells in the 
absence of BSH, points to the alpha particles generated in the nuclear fusion reaction as being 
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responsible for the measured enhancement of proton biological effectiveness. These findings, 
therefore, yield important implications for cancer protontherapy.  
 
Results 
Experimental approach 
The proton-boron nuclear reaction considered in this work is usually formalized as p+ 11B —> 3α. 
It has a positive Q-value (8.7 MeV) and is often referred to as the “proton-boron fusion reaction”, as 
the incident proton is completely absorbed by the 11B nucleus. This reaction has garnered interest 
since the 1930s (39, 40) because of the process’ ability to produce copious numbers of alpha 
particles in an exothermic reaction.	
According to the most recent studies and interpretations, p+ 11B —> 3α can be basically described 
as a two-step reaction (involving 12C and 8Be nuclei excitation) with a main resonance occurring at 
a 675 keV (center of mass energy) and where the maximum cross section of 1.2 barn is measured 
(44, 45). A more detailed description of the reaction is reported in Methods. 
The emitted alpha particles exhibit a wide energy spectrum with a predominant energy around 4 
MeV (46). Such a reaction has been considered very attractive for the generation of fusion energy 
without producing neutron-induced radioactivity (47,48). 
Such a nuclear reaction may be even more useful as it could play a strategic role in medical 
applications improving the effectiveness of protontherapy. The potential clinical use of the p-11B 
reaction has thus far only been theoretically investigated (49). Here we experimentally implement 
for the first time this innovative approach and actually measure the biological effects elicited by 
such a reaction. 
Besides the advantage of using a neutron-free nuclear reaction, the value of this method is also 
based on the fact that the the p + 11B à3α cross section becomes significantly high at relatively low 
incident proton energy, i.e. around the Bragg peak region. As schematically depicted in Fig.1, a 
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conventional proton beam used in protontherapy is drastically slowed down across the tumour, 
corresponding to the Bragg peak region. Thus, most of its energy (dose) is delivered to the tumour 
cells. Assuming a given concentration of 11B nuclei is present preferentially, but not exclusively, in 
the tumour, the presence of slow protons could trigger a series of fusion events generating alpha 
particles localized in the tumour region. In fact, most of the alpha particles generated in the proton-
boron reaction have an average range in water of less than 30 µm, comparable with typical cell size. 
Hence, even if such particles are mainly produced outside the cell cytoplasm due to sub-optimal 
boron uptake, the probability that they would reach the nucleus and damage the DNA remains very 
high. Moreover, even if a non-negligible concentration of 11B nuclei is present in the healthy tissues 
surrounding the tumour, the number of fusion events (i.e. generated alpha particles), will be 
relatively low or completely absent due the non-favourable incident proton energy fluence away 
from the tumour region. This would lead to a more biologically effective particle dose localization, 
higher than that currently achievable with conventional protontherapy, thus to a more efficient 
treatment in terms of an increase in cancer cell lethality because of the clustered nature of the DNA 
damage caused by the high-LET alpha particles emitted in the tumour region. Hence, protontherapy 
could acquire the benefits of an enhanced RBE for cancer cell killing, similar to 12C ion 
hadrotherapy but without the above-mentioned complications of the latter.  
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Figure 1 | Schematic representation of “conventional” radiotherapy by low-LET proton 
beams (A) and the rationale of boron-enhanced protontherapy (B).  
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The dose in protontherapy is currently released mainly in the tumor region (upper panel), cancer 
cells being represented here by purple circles and damaging events by black dots (A): proton-
induced damage is similar to that imparted to DNA by photons, consisting mainly of isolated 
lesions (middle and lower panels). If cancer cells are loaded with 11B-delivering agents (middle 
panel, B), as is the case with 10B-enriched compounds in BNCT, unrepairable DNA clustered 
lesions will be also produced by the high-LET alpha particles generated by the p-11B nuclear fusion 
reaction (lower panel). This in turn leads to the achievement of a greater RBE for cancer cell killing 
while maintaining beneficial sparing of surrounding healthy tissues (middle panel). 
	
BSH enhances cancer cell death following proton-irradiation  
To test whether the p + 11B à3α reaction results in an enhancement of cell killing by therapeutic 
proton beam irradiation, cells from the human prostate cancer line DU145 were irradiated with 
graded doses of the 60-MeV clinical proton beam available at the superconducting cyclotron of the 
INFN-LNS facility (Catania, Italy). Irradiations were performed in the presence of two 
concentrations of BSH (see Methods for details on the irradiation set-up and BSH pre-treatment). 
As a control, prostate cancer DU145 cells grown and irradiated without BSH were used. The 
considered BSH concentrations were equivalent to 40 ppm (parts per million) and 80 ppm of 11B. 
These were chosen based on values from the literature on the 10B-enriched BSH analogue used in 
BNCT in order to achieve the optimal 10B concentration (41, 50, 51). In particular, similar boron-
equivalent concentration ranges of another BNCT compound, BPA, had been previously used with 
the same cell line in vitro (52). Boron treatment enhanced proton irradiation biological effectiveness 
resulting in a significant increase in the induction of cell death in DU145 cells as measured by loss 
of colony-forming ability. Cells that were irradiated after pre-treatment with, and in the presence of, 
boron-containing BSH exhibited a greater radiosensitivity in comparison with cells exposed to 
radiation alone: BSH-treated cells yielded a much steeper clonogenic dose-response curve than that 
obtained for cells grown and irradiated in BSH-free medium (Fig. 2). The magnitude of radiation-
induced cell death was not affected by boron concentration. In our hands, the clonogenic survival 
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fraction SF was best fitted to a linear function of dose, i.e. SF = exp (-a*D). Measured survival 
curve parameters were a = (0.79 ± 0.04) Gy-1 for 80 ppm of 11B and a = (0.36 ± 0.06) Gy-1 for the 
dose response curve obtained in the absence of BSH, with a calculated RBE10 of 1.8. This indicated 
that protons in the presence of the boron compound were almost twice as effective at reducing cell 
survival by 90% compared to proton irradiation alone. Cellular radiosensitivity following low-LET 
proton irradiation was identical to that recorded after X-rays (Fig.2). At the concentrations used, 
BSH was not cytotoxic since the proliferative potential of unirradiated cells as given by cellular 
plating efficiency was not affected by the presence of BSH (Table 1). This means that the measured 
enhancement of proton effectiveness at cell killing was not contributed to by cytotoxicity caused by 
the boron-containing compound per se. 
 
 
Figure 2 | Boron-mediated increase in proton irradiation-induced cell death. Clonogenic dose 
response curves of prostate cancer cells DU145 irradiated with therapeutic protons in the presence 
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or absence of BSH. X ray-irradiation survival data are also shown for comparison. For the sake of 
clarity, shown curves refer to least-square fitting of data from proton irradiation in the absence of 
BSH (closed circles) and in the presence of the compound at the highest concentration used (80 
ppm, green squares). Data are weighted mean values plus standard error from at least two 
independent experiments. 
 
 Plating efficiency Baseline CA frequency 
No BSH 0.68 ± 0.13 0.024 ± 0.004 
40 ppm 11B 0.64 ± 0.17 0.023 ± 0.004 
80 ppm 11B 0.69 ± 0.11 0.018 ± 0.004 
Table 1: Cytogenotoxicity of BSH alone. Plating efficiency (PE) values and total chromosome 
aberration (CA) yields in unirradiated DU145 prostate cancer cells and normal epithelial MCF-10A 
cells, respectively, as a function of the amount of BSH. By definition, PE measures the survival of 
cells in the absence of radiation. Similarly, the recorded frequency of CAs in cells not exposed to 
radiation is referred to as baseline CA frequency.  
 
Induction and complexity of proton irradiation-induced DNA damage are exacerbated by 
BSH  
Radiation-induced structural chromosome aberrations (CAs) arise from mis- or un-rejoined DNA 
breaks due to erroneous repair (53, 54). Ionizing radiation can give rise to a wide spectrum of 
aberration types (55). Complex-type exchanges, defined as those rearrangements involving at least 
two chromosomes and generated by at least three breaks, are an archetypical feature of high-LET 
exposure (43, 56). Measurement of CA frequency and, in particular, quantification of the proportion 
of complex-type chromosome exchanges was therefore instrumental to assess a possible increase in 
radiation-induced genotoxicity and whether this could be ascribed to high-LET alpha particles 
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generated by the BSH-assisted p + 11B à3α nuclear reaction. Cancer cells are known to be 
genetically unstable, hence they do not lend themselves to reliable assessment of radiation-induced 
DNA damage. Radiation-induced chromosome rearrangements would superimpose onto an elevated 
confounding frequency of baseline damage. Therefore, the non-tumorigenic breast epithelial MCF-
10A cell line was chosen for scoring of radiation induced CAs. Proton irradiation resulted in a 
higher CA frequency in cells treated with BSH compared to cells irradiated with protons in the 
absence of BSH (Fig. 3). 11B concentration did not affect the measured frequency of radiation-
induced CA as shown by the similar induction of DNA damage between 40 ppm and 80 ppm of 11B. 
In addition, in cells not exposed to radiation, BSH per se did not cause significantly higher 
genotoxic damage compared BSH-untreated cells (Table 1). The yield of CAs following X-rays was 
basically identical to that measured after exposure to protons in the absence of BSH (Fig. 3). 
Aberration data were fitted to a linear –quadratic function of the type Y= Y0+a*D+b*D2 where the 
coefficient Y0 corresponded to the baseline CA frequency as reported in Table 1. Following 
irradiation in the absence of BSH, the values for the parameters were a = (0.003 ±0.021) Gy-1 and b 
= (0.024 ± 0.007) Gy-2, whereas a and b were (0.05± 0.03) Gy-1 and (0.021 ± 0.007) Gy-2 for proton 
irradiation in the presence of 80 ppm of 11B.  
Because of the purely quadratic nature of the dose-response curve for proton irradiation in the 
absence of BSH (the a parameter was not statistically different from zero), no estimate for RBEmax 
could be derived as this is defined as the ratio of the linear components of the linear-quadratic dose-
response curve (57). RBE values were calculated for two levels of damage instead, that is 10 and 20 
aberrations per 100 cells (58). In the case of 20 aberrations per 100 cell, the calculated RBE was 
about 1.4, whereas an RBE value of 1.7 was obtained for the level of 10 aberrations per 100 cells. 
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Figure 3 | BSH-induced increased induction of chromosome aberrations following proton 
irradiation. The dose-dependent frequency of all scored chromosome exchanges is shown for 
proton irradiation alone (black circles) and for proton irradiation in the presence of 11B at 
concentrations of 40 ppm (red circles) and 80 ppm (down triangles). X-ray data are also shown for 
comparison. In the interest of clarity, fitted curves are shown only for the highest boron 
concentration used (80 ppm, dashed line) and for irradiation with no boron compound (solid line). 
Data points correspond to the mean value measured in two independent experiments with standard 
errors of counts. 
 
Interestingly, a markedly pronounced occurrence of complex-type exchanges was found in samples 
treated with BSH compared to cells that had been irradiated with protons in the absence of BSH 
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(Fig. 4). After 0.5 Gy of protons the frequency of complex CAs ranged between 0.025 and 0.028 for 
BSH-treated cells as opposed to less than 0.004 in the case of cells irradiated in the absence of BSH. 
These values dramatically increased with dose and remained consistently higher in the case of BSH-
treated cells, reaching about 0.18 and 0.08 after 4 Gy of protons in the presence or the absence of 
BSH, respectively. Occurrence of complex-type exchanges following X-rays is also shown for 
comparison (Fig. 4) and does not differ from that measured for proton irradiation alone.  
 
Figure 4 | Induction of complex-type CAs. A greater proportion of complex chromosome 
rearrangements was found in cells irradiated with protons and treated with BSH than in cells subject 
to proton irradiation alone. 
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Figure 5 shows pictures of a non-aberrant chromosome spread, with the two pairs of painted 
homolog chromosomes 1 and 2 clearly visible, and of a cell with chromosome rearrangements of 
complex nature as several portions of the painted chromosomes are aberrantly joined with 
aspecifically stained chromosomes (appearing blue) and with themselves. Taken together, these 
results strongly suggest high-LET radiation-induced damage, thus consistent with the action of the 
alpha particles produced by the proton-boron fusion reaction. 
 
 
Figure 5| Analysis of proton irradiation-induced structural chromosome damage. 
Representative pictures of a non-aberrant normal chromosome spread (left) and of one from 4 Gy-
proton irradiated-MCF-10A cells treated with 80 ppm of 11B exhibiting a complex-type CA (right). 
 
Discussion 
For the first time, this work clearly proves that cellular irradiation with a clinical proton beam in the 
presence of a compound with natural boron isotopic content (80% of 11B + 20% of 10B) results in a 
significant enhancement of proton effectiveness at causing cytogenetic damage. The advantage of 
this new methodology is the fact that by using the considered fusion reaction, which has a high 
cross section for protons having energies up to 10 MeV, i.e. around the Bragg peak, the only 
products are three alpha particles with a range comparable to the cells’ dimensions. The compound 
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is BSH, one of the most commonly used boron-delivering agents in BNCT, where artificially 10B-
enriched BSH must be used to produce alpha particles. The rationale underlying BNCT is that if 
cancer cells are selectively drugged with 10B, thermal neutron irradiation will result in a highly 
localized and mostly lethal targeting of cancer cells because of the very short range and high LET 
of the produced alpha particles. However, despite numerous and carefully designed clinical trials, 
BNCT has never quite fulfilled its potential as a powerful cancer treatment modality both because 
of the intrinsically challenging quest for ideal carriers to deliver radiobiologically effective 
concentrations of boron to cancer cells, and of the availability of thermal neutron sources (41, 51). 
On the other hand, albeit already being a clinical reality, external beam 12C-ion hadrontherapy, 
which is capable of delivering very biologically effective radiation doses with extremely high 
precision to the tumor target, is hampered by economic and radiobiological issues as illustrated in 
the Introduction.   
Currently, the most widespread form of cancer treatment by accelerated charged particles is 
represented by protontherapy, which guarantees the same ballistic precision as 12C ion beams 
without the added complications. The disadvantage is a low biologically effectiveness since protons 
are only about as effective as photons and electrons at killing cells. The approach we propose and 
have successfully tested here could represent an enormous step towards the ability to increase the 
biological efficacy of proton radiotherapy by coupling the already favorable spatial and 
radiobiological characteristics of protons with the capacity to trigger the proposed reaction 
exclusively inside the tumor. In principle, this would enable the avoidance of the intrinsic 
uncertainties and enormous handling complications associated with the use of neutron beams in 
BNCT and could lead to an increase of proton biological effectiveness towards values closer to 
those exhibited by 12C-ions.  
The biological effects of the proton-boron fusion reaction were investigated by measuring 
clonogenic cell death and chromosome aberrations (CAs) in a prostate cancer cell line (DU145) and 
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in a non-tumorigenic epithelial breast cell line (MCF-10A), respectively. The latter was best suited 
to investigate chromosomal damage unlike genomically unstable cancer cells.  	
We found that proton irradiation-induced cellular lethality was greatly enhanced by irradiating cells 
that had been pre-treated with BSH. In particular, our results for survival of DU145 cells following 
low-LET proton irradiation alone are in line with those obtained at another protontherapy facility by 
Polf et al. (59), who studied the radiosensitizing effects of Au nanoparticles. These authors actually 
reported an enhancement of proton biological effectiveness of smaller magnitude than that found by 
us and aided by the p + 11B à3α reaction. Moreover, cellular survival values found by us following 
proton-triggered alpha irradiation from BSH are essentially identical to those found by Yasui et al. 
(52), exposing DU145 cells to neutrons in the presence of BPA, the other most common boron-
delivering agent together with BSH. 
Investigation of structural DNA damage in the form of CAs not only confirmed that the 
effectiveness of cellular proton irradiation is enhanced by the presence of boron but it also strongly 
suggests that such an enhancement could be explained by the action of high-LET radiation, e.g. 
alpha particles emitted by p + 11B à3α reaction. Firstly, a greater aberration frequency was found 
among BSH-treated cells. Following the highest dose of protons used (4 Gy) in the presence of 40 
ppm of 11B, the observed frequencies of dicentrics (0.144 ±0.004) and rings (0.064±0.008) are 
consistent with those of 0.171 ±0.0175 and 0.029 ± 0.007, respectively, found by Schmid et al. (60) 
in human lymphocytes at the highest dose of thermal neutrons used by them (i.e. 0.248 Gy) and at a 
similar 11B-equivalent concentration (30 ppm). In addition, a significantly higher proportion of 
complex chromosome rearrangements in BSH-treated cells compared to controls following proton 
irradiation was found pointing to an LET-dependent effect since complex CAs are a well-known 
cytogenetic signature of exposure to high-LET radiation. In fact, it is well known that the greater 
biological effectiveness of densely ionizing radiation is a direct consequence of the physical pattern 
of energy deposition events along and around its tracks. Low-LET ionizing radiation such as x- or 
	 17	
g-rays mainly damage cells through short-lived bursts of free radicals (e.g. reactive oxygen species), 
generated by its interaction with the intracellular environment. This causes isolated lesions at the 
DNA level, the most detrimental of which for cell survival are double-strand breaks (DSBs). 
However, the much denser thread of ionization events specific to track-structured high-LET particle 
radiations, results in many closely spaced clusters of multiply DNA damaged sites, comprising 
DSBs together with single-strand breaks and damaged bases, which cause the cellular repair system 
to be error-prone. Hence, such lesions either are left unrepaired, which explains the greater 
efficiency of high-LET radiations at cell killing, or undergo misrepair. In the latter case, since single 
densely ionization tracks can simultaneously  cause breaks in far apart stretches of DNA, i.e. 
belonging to separate chromosome domains, defective repair will lead to a higher frequency of 
DNA mis-rejoining events occurring between several chromosomes that after low-LET radiation, 
the so-called complex-type exchanges. In BSH-treated irradiated cells, the proportion of such 
complex-type aberrations relative to total exchanges ranged between 30% and 42% while that for 
proton irradiation alone was between 6% and 15%. Moreover, the ratio of complex- to simple-
exchanges found by us ranged between 0.59 and 0.71, similar to the figure of 0.64 found by others 
for 0.5 Gy of direct alpha particle irradiation in first-division human lymphocytes scored with the 
same technique used by us, i.e. FISH painting (61). 
We did not perform measurements of actual 11B incorporation by cells but both drug pre-treatment 
times and concentrations were chosen according to available literature in BNCT studies showing 
the best conditions to achieve the ideal boron concentration in cells (20 µg per grams of tissue or 
109 atoms per cell). Indeed, although 10B-enriched BSH is known for its poor permeabilization 
through cell membranes, its use is facilitated by the higher boron content compared to the other 
widely used boron-delivering compound, BPA. However, the alpha particles emitted via the p + 11B 
à3α reaction have average energies around 4 MeV corresponding to ranges in tissues of a few tens 
of microns, which ensures that severe cellular DNA damage is caused even if BSH is not 
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incorporated in the cell but sits on its membrane. Moreover, the ballistic properties of the incident 
proton beam whereby proton energies drastically decrease in correspondence with the tumour 
volume, ensure negligible nuclear fusion events even in the worst-case scenario where the delivery 
agent containing 11B nuclei is also present in the healthy tissues surrounding the tumour. 
Furthermore, the presence of 10B in the proposed method allows to trigger different nuclear 
reactions generating prompt gamma-rays, which could be potentially used in a simultaneous 
treatment-and-diagnostics approach (49,62,63). 
In conclusion, if further confirmed by both in vitro and pre-clinical investigations, our results 
represent an important breakthrough in cancer radiotherapy, particularly in the treatment of the 
disease by accelerated proton beams since it may significantly enhance its effectiveness without 
foreseeable patients’ health complications and added financial costs. 
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Methods 
Cell cultures. Prostate cancer cell line DU145 and the spontaneously immortalized, 
nontransformed human mammary epithelial MCF-10A cells (kindly donated by prof. K. Prise, 
School of Medicine, Dentistry and Biomedical Sciences, QUB, UK) were grown in 25-cm2 (T25) 
standard tissue culture flasks, routinely subcultured and maintained at 37°C in a humidified 
atmosphere (95% air, 5% CO2). DU145 cells were used to assess possible enhancement by boron of 
proton-induced cancer cell death while chromosomal DNA damage was investigated in MCF-10A 
cells. DU145 cells were grown in RPMI medium supplemented with 10% fetal bovine serum and 
1% antibiotics. Two media were instead needed for MCF-10A cells, one for optimal growth 
conditions and the other for resuspension and quenching of trypsin, as described in detail by 
Debnath et al. (64) Two days before irradiation DU145 and MCF-10A cells were seeded in T25 
flasks at 105 and 6 105 cells/flask, respectively.  
BSH preparation and treatment. A 1-g vial of sodium mercaptododecaborate or N-BSH, Na2 
[B12H11SH], FW 219.87, was purchased from KATCHEM Ltd. (Czech Republic). The working 
concentrations of 80 and 40 ppm of 11B corresponded to 0.17 mg/ml and 0.08 mg/ml of BSH, 
respectively. BSH was decanted at the necessary amounts according to the total volume of the 
medium, in which the compound was thoroughly dissolved by simple agitation just prior to cell 
treatment. Boron cellular conditioning started 7 hrs prior to irradiation: the cell growth medium was 
aspirated and replaced with 5 ml of BSH-containing medium. Ordinary BSH-free growth medium 
was replaced into flasks that were used as controls. Just before irradiation, flasks were completely 
filled with the respective media (with or without BSH) to prevent cells from drying since flasks are 
irradiated standing vertically in front of the beam. 
p + 11B à3α nuclear fusion 
The p + 11B à3α nuclear fusion reaction at low energy can be basically described as a two-step 
reaction due to its behaviour at the three resonant energies (0.162 MeV, 0.675 MeV and 2.64 MeV). 
Firstly, a proton, interacting with 11B, induces the formation of a 12C* compound nucleus formed in 
the 2- or 3- excited state. If the 12C* nucleus is formed in its 2- state, it will decay to the first 2+ 
state of 8Be emitting one alpha-particle with l = 3 (65). If the 12C* nucleus is formed in its 3- state, 
then the primary alpha particle can be emitted either with l = 1 from the decay to the first 2+ 8Be 
excited state, or with l=3 from the decay to the 0+ 8Be ground state. In either case, the remaining 
8Be (2+ or 0+) nucleus immediately decays into two secondary alpha-particles with l' = 2. Alpha 
particles emitted in the first stage present a well-defined energy distribution and are commonly 
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referred to as α0 and α1 if the 8Be 2+ or the 0+ states are populated, respectively. A few authors 
(65, 66) report that a very unlikely fourth channel, characterized by a maximum cross section of 10 µb in 
the 2.0 - 2.7 MeV energy range (66), can also be activated. In this case the 12C* directly breaks into three a 
particles skipping the intermediate 8Be stage, which show a continuous energy distribution.  
Figure 5 reports some of the available experimental data (65,66) for the total production cross section of the 
p + 11B à3α reaction as function of the mass centre energy and for the a1 channel. For low energies (0.1-5 
MeV) the reaction cross sections become significantly high, thus maximising the alpha particle production 
around the proton Bragg peak region, an advantageous feature for the alternative protontherapy approach 
proposed in this work. 
 
Figure 5| Experimental cross sections for proton-11B and the a1 channel. 
 
Irradiation. Irradiations were performed using the 62-MerV proton beam generated by the superconducting 
cyclotron clinically used at the CATANA (Centro di AdoTerapia ed Applicazioni Nucleari Avanzate) 
(67,68) eye proton therapy facility of the Italian Institute for Nuclear Physics in Catania, Italy. The 
CATANA irradiation setup for biological samples is described in detail elsewhere (69). The clinical Spread 
Out Bragg Peak (SOBP) range was 29 mm in water and cells were positioned at the depth of 18 mm water 
equivalent (calculated incident LET ~ 5 keV/mm), to the middle of the SOBP. Absolute absorbed dose is 
measured in water, by means of a plane-parallel PTW 34045 advanced-type Markus ionisation chamber, 
according to the International Atomic Energy Agency Technical Report Series 398 Code of practice. Overall 
uncertainty in absolute dose measurement is kept within 1.5%. Details on the irradiation beamlines, 
0,1 1 10
10-1
100
101
102
103
 W. Buck (1983)
 H.W. Becker (1987)
 R.E. Segel (1965)
Centre of Mass Energy (MeV)
C
ro
ss
 S
ec
tio
n 
(m
b)
	 21	
dosimetric procedures and related uncertainties for irradiation conditions can be found elsewhere (68). For 
measurement of cell killing, proton doses of 0, 0.5,1,2, 3 Gy were used. For 80 ppm of 11B the effects of a 
dose of 4 Gy were also tested. One cell culture flask was used for each dose for all BSH concentrations in 
each experiment. For chromosome aberration studies, three doses were used: 0.5, 2 and 4 Gy. Two flasks per 
dose were used for all BSH concentrations. Two independently repeated experiments were performed for 
both endpoints.  
Measurement of cell death. Radiation-induced cell death was assessed by means of the clonogenic test, the 
gold standard for measuring cellular radiosensitivity. According to this assay, a cell survives irradiation if it 
retains its proliferative potential and it is thus capable of forming a colony composed of at least 50 cells.  
After irradiation, the medium was discarded from the flasks, and DU145 cells were detached, counted by 
haemocytometer and re-plated at opportune densities. They were then allowed to grow for colony formation 
in BSH-free medium. Four replicates for each dose were used for statistical data robustness. Clones were 
fixed and stained by crystal violet after 10 days. Surviving fractions (SF) are obtained by dividing the 
number of clones by the number of cells seeded at a given dose D, normalized by the plating efficiency (PE), 
that is the “surviving” of cells in the absence of radiation according to the expression SFDoseD = [Number of 
clones/number of cells]DoseD/(PE). Experimental data were initially fitted to the linear-quadratic equation that 
best describes low-LET radiation induced cell death SF = exp (-a*D-b*D2). In all cases, however, the b 
parameter was found to be consistent with zero. 
Chromosomes aberration analysis. After irradiation, MCF-10A cells were kept in BSH-free medium for up 
to36 h. Genotoxic action of radiation was studied by scoring structural aberrations in chemically induced 
interphase chromosomes according to the Premature Chromosome Condensation (PCC) technique. Cells 
were incubated for 30 min with calyculin A (50 ng/mL, Sigma-Aldrich) for PCC induction as elsewhere 
described (70). To collect PCC spreads, cells were trypsinized, centrifuged at 300g for 8 min, then the pellet 
was resuspended for 25 min in hypotonic solution (75 mM KCl  at 37°C), and fixed on ice in freshly 
prepared Carnoy solution (3:1 v/v methanol/acetic acid). Spreads were then dropped on pre-warmed (42 °C) 
wet slides and air-dried at room temperature.	Fluorescence In Situ Hybridization painting was conducted by 
using whole-chromosome fluorescence-labelled DNA painting probes directed to chromosomes 1 and 2 
following the manufacturer’s recommendations (MetaSystems, Germany). Denaturation (72°C for 3 min) 
followed by hybridization (37°C overnight) of slides was performed using a hand-free HYBrite chamber 
system. Unlabeled chromosomes were counterstained with 12 ml 4,6-diamidino-2-phenylindole (DAPI) 
staining. Slides were viewed with an epi-fluorescence microscope connected to a computer-controlled 
system (Metafer 4 software, MetaSystems,) for automated slide scanning and three-color image acquisition. 
Chromosome analysis was carried out on stored images. Scoring was conducted blind by the same scorer. 
Not less than 500 chromosome spreads for each dose were scored (at least 1,500 for nonirradiated controls). 
All types of aberrations were scored separately and categorized as simple exchanges (i.e. translocations and 
dicentrics), either complete or incomplete, acentric fragments and complex exchanges. For this study’s 
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purpose, however, data herein presented are relative to the total chromosomal exchange frequency and to the 
complex-type exchange frequency. Frequency of total aberration exchanges was fitted to the equation Y = 
Y0+a*D+bD2. 
 
Statistical analysis 
For analysis of the dose – response relationships for cell killing and chromosome aberration frequency, curve 
fitting was performed by nonlinear least square minimization (Marquardt’s algorithm) using SigmaPlot 12.5 
software (SPSS, USA). Poisson statistics was assumed to derive standard errors on aberration frequencies. 
Experimental surviving fraction data in clonogenic assays are affected by several sources of errors, such as 
those associated with cell counts and cell dilutions, which are not taken into account by simple calculations 
of the standard error affecting colony counting. A more precise approach is needed to determine the 
experimental error on the plating efficiency PE as above defined and here recalled for convenience:  𝑃𝐸 = 	 𝑋&'(')*+,𝑋&+((, 	0	𝐺𝑦 
This quantity is the ratio between two mean values, i.e. the mean counted colony number and the mean 
number of cells seeded, each with its standard error SE: SEcolonies and SEcells. Therefore, according to the 
standard formula on error propagation, the standard error for plating efficiency, i.e. SE (PE), can be derived 
as follows: 
𝑆𝐸 𝑃𝐸 = 	 𝜕𝑃𝐸𝜕𝑋&'(')*+, 2 𝑆𝐸&'(')*+, 2 + 𝜕𝑃𝐸𝜕𝑋&+((, 2 𝑆𝐸&+((, 2 	= 1𝑋&+((, 2 𝑆𝐸&'(')*+, 2 + −𝑋&'(')*+,𝑋&+((,2 2 𝑆𝐸&+((, 2 
 
Recalling the definition of Surviving Fraction at a given dose D: 
𝑆𝐹7 = 	 𝑋&'(')*+,𝑋&+((, 𝑃𝐸 
In the interest of simplicity, it can be assumed that the mean number of cells seeded that appears in the above 
formula is devoid of error, which is is reasonable since cell counting error is taken care of in the SE (PE) . 
This means treating 𝑋&+((, as a constant; hence we can define  89:;:<=>?89>;;?  as SF, with its error being 
(SEcolonies)/(	𝑋&+((,) 
Hence, SE(SFD) can be determined as follows: 
𝑆𝐸 𝑆𝐹7 = 	 1𝑃𝐸 2 	𝑆𝐸&'(')*+,𝑋&+((, 2 + − 𝑆𝐹𝑃𝐸 2 2 𝑆𝐸 𝑃𝐸 2 
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In these calculations we assumed that observed CV is always greater than Poisson CV on all counts, of either 
colonies or cells; wherever this was no the case, we corrected the experimental SE by multiplying the mean 
(of cell or colony counts) by the Poisson CV. 
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